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INTRODUCTION
Abnormalities in testicular function have been reported
in most men after allogeneic bone marrow transplantation
(alloBMT) [1-8]. These abnormalities are attributed to the
total body irradiation and alkylating chemotherapy agents
used in the myeloablative regimens of bone marrow trans-
plantation [3,8,9]. Testicular dysfunction is manifested by
elevated follicle-stimulating hormone [FSH] and luteiniz-
ing hormone [LH] levels and oligospermia or azoospermia
[1-9]. Germinal center aplasia and destruction of the Sertoli
cells have been seen on testicular biopsies. Testosterone-
producing Leydig cells appear normal on biopsy, and previ-
ous reports describe normal basal testosterone levels in men
after transplantation [1-7,9]. Male sexual function has also
been assessed after alloBMT. Decreased libido or difﬁculty
achieving an erection is reported in approximately 25% of
these patients [4,8,10,11].
Assessment of male sexual function after autologous
BMT (autoBMT) is lacking, and assessment results may be
different from the outcomes reported after allotransplanta-
tion. Patients undergoing autoBMT differ from those
undergoing allotransplantation. For example, male patients
undergoing autoBMT are more likely to have Hodgkin’s
disease and testicular damage from induction and salvage
chemotherapy than those undergoing allotransplantation
[11-16]. Furthermore, patients undergoing autoBMT may
be older than recipients of alloBMT. In addition, they do
not require posttransplantation immunosuppressive therapy
and do not experience graft-versus-host disease, although
the impact of these latter factors is unknown.
Few studies have assessed male sexual function after
autoBMT [6,17,18]. Keilholz et al. [17] studied 19 patients,
of whom 13 had elevated FSH levels, 3 had elevated LH
levels, and none had abnormal testosterone values. The
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ABSTRACT
Although endocrine dysfunction has been reported in survivors of allogeneic bone marrow transplantation
(alloBMT), data for autologous BMT (autoBMT) recipients are lacking. Because information on male potency in
particular is scanty, we prospectively assessed male sexual function after autoBMT. We identified 16 men who were
≤50 years of age at the time of evaluation and disease free for at least 6 months after autoBMT. Nine had Hodgkin’s
disease, 4 had acute myelogenous leukemia, and 3 had non-Hodgkin’s lymphoma. Blood samples were assayed for
luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone. Patients were surveyed with a
modified version of the Pyschosocial Adjustment to Illness Scale regarding erectile dysfunction and loss of interest
in sexual activities. Seventy five percent of the men reported normal interest in sexual activities and 87.5% reported
normal erectile function; however, 4 of 16 reported a moderate loss of interest in sexual activities, and another 2 of
16 reported frequent loss of erectile function. All 4 men with decreased libido and both men with impaired erectile
function had Hodgkin’s disease. Fourteen (88%) of 16 patients had an elevated FSH level, 7 (47%) of 15 had ele-
vated LH, and 6 (38%) of 16 had decreased testosterone levels. Decreased testosterone levels correlated with a
moderate or total loss of libido (P = .008) and a diagnosis of Hodgkin’s disease (P = .01). Thus, after transplantation,
most men have abnormal levels of gonadotrophins. Decreased levels of testosterone and symptoms of sexual dys-
function correlated with a diagnosis of Hodgkin’s disease and may be related to the induction and salvage therapy
received prior to autoBMT.
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study, however, did not document symptoms of sexual dys-
function. Chatterjee et al. [18] studied 13 men 3 months
after autoBMT for relapsed non-Hodgkin’s lymphoma or
Hodgkin’s disease. They reported that all 13 men had
azoospermia and increased FSH and LH levels after
autoBMT. Basal testosterone levels were unchanged after
autoBMT, but β human chorionic gonadotrophin (HCG)-
stimulated testosterone levels were decreased after autoBMT
compared to pretransplantation levels and levels in healthy
control subject.
Here, we report a study of male sexual function after
autoBMT that documented the patients’ symptoms and hor-
mone levels.
PATIENTS AND METHODS
We identified 17 consecutive male patients from the
University of Toronto Autologous Bone Marrow Transplant
Program who were aged 50 years or less at the time of eval-
uation and were disease free at least 6 months after
autoBMT. One patient was excluded because he was receiv-
ing testosterone injections at the time of evaluation. All
patients had a normal performance status (Eastern Coopera-
tive Oncology Group, grade 0). Of the 16 patients in the
study, 9 had Hodgkin’s disease, 4 had acute myelogenous
leukemia (AML), and 3 had non-Hodgkin’s lymphoma. All
patients received etoposide (VP-16), 60 mg/kg, and melpha-
lan, 140-180 mg/m2, as intensive therapy according to our
previously reported protocol [19]. The 4 patients with AML
also received total body irradiation (500-1200 cGy). During
induction chemotherapy, the 9 patients with Hodgkin’s dis-
ease received ABVD (adriamycin, bleomycin, vinblastine,
daccarbazine) (5 patients), MOPP/ABV (mechlorethamine,
vincristine, procarbazine, prednisone/ABV) (1 patient),
MOPP/ABVD (1 patient), ProMACE-CytaBOM (pred-
nisone, vincristine, doxorubicin, methotrexate, cytosine ara-
binoside, bleomyein, cyclophosphamide, etoposide) (1
patient), or VACOP-B (etoposide, doxorubicin, cyclophos-
phamide, vincristine, prednisone, bleomycin) (1 patient).
These 9 patients received salvage chemotherapy consisting
of mini-Beam (carmustine, etoposide, cytosine, arabinoside,
melphalan) (8 patients) and/or DHAP (dexamethasone,
cytosine, arabinoside, cisplatin) (3 patients). None received
pelvic irradiation during induction or consolidation therapy.
Following appropriate institution-approved consent,
patients completed a questionnaire regarding symptoms of
erectile difficulties and interest in sexual activities. The
questions were modeled on the self-report version of the
Psychosocial Adjustment to Illness Scale [20] that has been
validated in lung cancer and renal dialysis populations. The
survey questioned patients about their recent sexual activi-
ties and their sexual activities during the 6 months preced-
ing autoBMT. Patients were also asked about their loss of
ability to achieve erections either spontaneously or with
physical stimulation. They were asked to rate the occur-
rence of this loss of ability to achieve erections as (1) not at
all or only occasionally, (2) frequently, or (3) completely.
The patients were asked whether they experienced a loss of
interest in sexual activities and rate it as (1) no loss, (2) slight
loss, (3) moderate loss, or (4) total loss of interest in sexual
activities. Blood samples were collected after completion of
the survey and assayed for FSH, LH, and total testosterone
levels. One patient did not have an LH level assayed. One
patient had a free testosterone level assayed rather than a
total testosterone level.
All protocols and consent forms were approved by the
Human Subjects Review Committee of the Toronto Hospital.
RESULTS
The median age of the 16 patients at transplantation was
36 years (range, 20-49 years). They were evaluated a median
of 3 years after autoBMT (range, 7 months to 8 years)
and had a median age at evaluation of 39 years (range,
24-50 years).
Hormone Levels
Almost all patients had abnormal hormone levels. FSH,
LH, and total testosterone levels for the patients in the
study are shown in the ﬁgure. Fourteen (88%) of 16 patients
Hormone levels after autologous bone marrow transplantation
(autoBMT). Sixteen patients were evaluated a median of 3 years after
autoBMT. Blood samples were drawn at the time of evaluation and
assayed for follicle-stimulating hormone (FSH) (A), luteinizing hor-
mone (LH) (B), and total testosterone (C). The normal range is delin-
eated by the dark rectangle.
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had an elevated FSH level, 7 (48%) of 15 patients had ele-
vated LH levels, and 6 (38%) of 16 had decreased serum
testosterone levels. All 6 patients with decreased testos-
terone levels had elevated FSH levels, and 4 of 6 had
increased LH levels. By Fisher exact analysis, decreased
testosterone levels correlated with a moderate or total loss
of interest in sexual activities (P = .008) and a diagnosis of
Hodgkin’s disease (P = .01). Four of 6 patients with
decreased testosterone levels had decreased libido and all
6 with decreased testosterone levels had Hodgkin’s disease.
Abnormal testosterone levels did not correlate with the age
of the patient at transplantation (P = .6) or with the time
from transplantation to evaluation (P = .6). The median age
at transplantation of the men with low testosterone levels
was 32 years (range, 24-47 years) compared to 41 years
(range, 20-50 years) for the men with normal testosterone
levels. The median time from transplantation to evaluation
of the men who had decreased testosterone levels was
3.4 years (range, 1.6-6 years) compared to 1.4 years (range,
0.67-8 years) for the men with normal testosterone levels.
Survey Results
At the time of evaluation, 88% of the study patients
reported no erectile dysfunction. Only 2 of 16 (12%)
reported frequent loss of the ability to achieve an erection
either spontaneously or with physical stimulation. None of
the men had a complete loss of ability to achieve erections.
Four of the 16 (25%) had a moderate loss of interest in sex-
ual activities at the time of evaluation, however, 3 of the
4 had symptoms that predated their transplantation. None
of the men had a total loss of interest in sexual activities.
Six patients noted some improvement in their libido
between the 6 months preceding their autoBMT and the
time of their evaluation. In 1 case, a patient attributed his
decreased interest in sexual activities to the fear his Hick-
man line would fall out. Once the line was removed after
autoBMT, his interest in sexual activities returned to nor-
mal. Both patients with impaired erectile function and all
4 patients with decreased libido had Hodgkin’s disease.
DISCUSSION
In our study, 14 of 16 patients had abnormal gonado-
trophin levels. Elevated FSH level is a common ﬁnding after
BMT and is attributed to damage to the germinal centers of
the testicles by the total body irradiation and the alkylating
agents in the myeloablative regimens [1-9]. In our study,
6 of 16 patients had decreased testosterone levels. Decreased
testosterone levels correlated with symptoms of decreased
interest in sexual activities and a diagnosis of Hodgkin’s dis-
ease. Decreased testosterone level also may reﬂect a longer
time from transplantation to evaluation.
To our knowledge, no previous studies have reported
abnormal basal testosterone levels after BMT. Hormone
levels prior to transplantation were not assayed in our
patients, so we cannot tell whether the abnormalities are
due to the induction or salvage therapies the patients
received or to the autoBMT intensive therapy regimen.
Although the lack of pretransplantation hormone levels is a
limitation to this study, sexual dysfunction is not likely a pri-
ority to patients battling relapsed disease. This issue really
concerns long-term survivors of BMT, so it is the posttrans-
plantation levels that are most important.
The association between decreased testosterone level
and Hodgkin’s disease suggests that this abnormality may
predate the autoBMT. Alternatively, the therapy for Hodgk-
in’s disease may produce subclinical damage that is exacer-
bated by autoBMT. Chatterjee et al. [18] evaluated patients
3 months after autoBMT and described decreased testos-
terone production after βHCG stimulation compared with
pretransplantation levels and normal controls. This ﬁnding
implies that the intensive therapy damages the testosterone-
producing Leydig cells.
Hodgkin’s disease itself and its treatment have been
associated with testicular damage [12-16,21]. In one study,
33% of men with Hodgkin’s disease had decreased sperm
counts before treatment [16]. After 2 cycles of MOPP
chemotherapy, >90% of men have been found to be ren-
dered persistently azoospermic, and testicular biopsy has
revealed atrophy of the Sertoli and Leydig cells and absence
of the germinal epithelium [12,13,21]. About half of the
men who did not receive pelvic irradiation recovered sper-
matogenesis after induction with MOPP chemotherapy
[13]. After alternating MOPP/ABVD induction chemo-
therapy, 87% of men were azoospermic, although 40%
recovered spermatogenesis [16]. After induction therapy
with ABVD, 54% of men developed azoospermia, but all
recovered spermatogenesis [22].
The effect of induction therapy for Hodgkin’s disease on
testosterone levels is less clear. In one study of men treated
with MOPP/ABVD, there was no significant decline in
testosterone levels after treatment, but the mean serum LH
and FSH levels were elevated [16]. In contrast, a study of
patients with Hodgkin’s disease treated mainly with MVPP
(mechlorethamine, vinblastine, prednisone, procarbazine)
found a lower mean plasma testosterone level when com-
pared with a group of healthy control subjects. However,
none of these patients had testosterone levels below the nor-
mal level [21]. Most of the men with Hodgkin’s disease in
our study received only ABVD induction therapy and none
received only MOPP as induction.
None of our patients reported fathering a child after
autoBMT, but patients were not questioned regarding their
frequency of attempts. Several men have fathered children
after alloBMT [1,3,23], and 3 conceptions have been docu-
mented after autoBMT [17,23]. In these studies, all men
who conceived had normal FSH and testosterone levels
after transplantation.
In our study, 12% of men reported significant erectile
dysfunction, and 25% reported a moderate loss of interest
in sexual activities at the time of evaluation. These values
compare favorably with the results reported by others
regarding sexual dysfunction after alloBMT. In the study
by Wingard et al. [10], which included 82 men after allo-
transplantation, 24% reported difficulties with erections
and 13% described difficulty with ejaculation. Difficulties
in erectile function correlated with a shorter time from
transplantation and poor performance status. No compari-
son was made of patients’ symptoms prior to transplanta-
tion. Syrjala et al. [11] reported that 29% of men experienced
at least 1 sexual problem within 3 years after transplantation.
These researchers noted that more men reported problems
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with arousal and achieving erections than with orgasms
and maintaining erections. In their study, older age, not
being married, and greater pretransplantation psychologi-
cal distress were predictive of decreased sexual satisfaction
at 3 years posttransplantation. In a study by Watson et al.
[24], 44% of patients experienced a decline in interest in
sexual activity after autotransplantation for AML. Sexual
dysfunction was associated with decreased quality of life,
increased fatigue, and worse emotional functioning.
The incidence of erectile dysfunction that we and others
have reported is comparable to that in the general popula-
tion, but the incidence of decreased libido among transplan-
tation patients appears higher than that in men who have
not undergone transplantation. The National Health and
Social Life Survey obtained information from 1410 English-
speaking men selected at random from households in the
United States. In this population, 9% of men aged 30 to 39
years and 11% of men aged 40 to 49 years reported difﬁ-
culty achieving or maintaining an erection. Lack of interest
in sexual activity was reported by 13% of men aged 30 to
39 years and 15% of men aged 40 to 49 years. In this study,
poor health and emotional distress were risk factors for sex-
ual dysfunction [25].
In contrast, Molassiotis et al. [26] described the inci-
dence of sexual dysfunction among 29 men a mean of 36
months after allotransplantation or autotransplantation and
compared the results with those found in healthy subjects. In
this study, 38% of transplantation patients reported erectile
dysfunction and decreased interest in sexual activity. The
incidence of erectile dysfunction was higher in the transplan-
tation group than in control subjects, but rates of decreased
sexual desire did not differ in the transplantation group com-
pared with healthy control subjects. None of the transplanta-
tion patients in this study had decreased testosterone. It is
unclear why such relatively high levels of erectile dysfunction
were observed in the BMT patients and healthy controls.
There are a number of limitations to our study. First,
the number of patients enrolled is small. As a result, the
lack of association between decreased testosterone levels
and the patients’ ages and the times from autoBMT may be
due to a lack of power to detect a difference. In addition,
the correlation between Hodgkin’s disease and sexual dys-
function and abnormal testosterone level may also simply
reflect the small sample size. However, we speculate that
many of the abnormalities detected may be due to induc-
tion and salvage therapy received prior to autoBMT and
not to the autoBMT intensive therapy regimen. Alterna-
tively, autoBMT may exacerbate subclinical damage to the
testosterone-producing Leydig cells. A larger study would
be required to test these hypotheses and would require
samples from patients prior to transplantation. The second
limitation is that this study did not deﬁnitively address the
cause of sexual dysfunction in these patients. Decreased
testosterone level may be only 1 of several contributing
causes of the sexual dysfunction that we observed. For
example, emotional distress can impact patients’ libido and
erectile function, and higher levels of emotional distress are
seen in patients after transplantation [24]. In addition,
patients were asked about the loss of ability to achieve erec-
tions either spontaneously or with physical stimulation, but
this question was not subdivided to differentiate between
difﬁculties achieving erection experienced during masturba-
tion and those experienced with partners. If the erectile
function was normal during masturbation and the dysfunc-
tion was confined to encounters with partners, it would
suggest a psychosocial cause for the erectile dysfunction.
Therefore, future studies should measure other psychologi-
cal parameters and obtain a detailed description of the erec-
tile dysfunction to determine the proportion of the sexual
dysfunction due to endocrine abnormalities and that due to
psychological abnormalities.
In conclusion, following autoBMT, the majority of men
have abnormal gonadotrophin levels, and over one third
have decreased testosterone levels. None of the men in our
study reported complete loss of erectile function or total
loss of interest in sexual activity, and most described their
sexual function after autoBMT as normal. Both sexual dys-
function and abnormal testosterone levels correlated with a
diagnosis of Hodgkin’s disease. Although the number of
patients in the study was small, this association is intriguing
and invites a larger study to validate these findings and
determine the cause of decreased testosterone level and sex-
ual dysfunction after transplantation.
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